{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:21:08Z","timestamp":1788992468575,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clml.2023.12.010","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T19:33:22Z","timestamp":1703100802000},"page":"e130-e137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm"],"prefix":"10.1016","volume":"24","author":[{"given":"Naveen","family":"Pemmaraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Garnache-Ottou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Gabarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton J.V.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Moshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2023.12.010_bib0001","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","article-title":"Clinical and biologic features of CD4(+)CD56(+) malignancies","volume":"99","author":"Feuillard","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.12.010_bib0002","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1309\/GJWNPD8HU5MAJ837","article-title":"Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review","volume":"123","author":"Petrella","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.clml.2023.12.010_bib0003","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1309\/FY6PK436NBK0RYD4","article-title":"CD4+\/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells","volume":"127","author":"Herling","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2023.12.010_bib0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","article-title":"Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm","volume":"73","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.clml.2023.12.010_bib0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2020.01.010","article-title":"Cutaneous lymphoma in Japan, 2012-2017: a nationwide study","volume":"97","author":"Fujii","year":"2020","journal-title":"J Dermatol Sci"},{"issue":"19","key":"10.1016\/j.clml.2023.12.010_bib0006","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","article-title":"Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients","volume":"4","author":"Laribi","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.clml.2023.12.010_bib0007","doi-asserted-by":"crossref","first-page":"19204","DOI":"10.18632\/oncotarget.4146","article-title":"Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile","volume":"6","author":"Mart\u00edn-Mart\u00edn","year":"2015","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.clml.2023.12.010_bib0008","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?","volume":"3","author":"Garnache-Ottou","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2023.12.010_bib0009","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","article-title":"Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis","volume":"12","author":"Togami","year":"2022","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.clml.2023.12.010_bib0010","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3324\/haematol.2010.026179","article-title":"Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications","volume":"95","author":"Jegalian","year":"2010","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2023.12.010_bib0011","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/s41375-023-01968-z","article-title":"Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies","volume":"37","author":"Cuglievan","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2023.12.010_bib0012","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2023.12.010_bib0013","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.12.010_bib0014","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","article-title":"Identification of a leukemic counterpart of the plasmacytoid dendritic cells","volume":"97","author":"Chaperot","year":"2001","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.12.010_bib0015","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/leu.2014.64","article-title":"Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition","volume":"28","author":"Sapienza","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.12.010_bib0016","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2006-04-018143","article-title":"Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities","volume":"109","author":"Dijkman","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.12.010_bib0017","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2023.12.010_bib0018","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23567","article-title":"TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow","volume":"88","author":"Alayed","year":"2013","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2023.12.010_bib0019","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","article-title":"Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis","volume":"5","author":"Renosi","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2023.12.010_bib0020","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1084\/jem.185.6.1101","article-title":"The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand","volume":"185","author":"Grouard","year":"1997","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.clml.2023.12.010_bib0021","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1182\/blood-2002-10-3297","article-title":"TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin","volume":"101","author":"Herling","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.12.010_bib0022","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2004-06-2416","article-title":"Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells","volume":"105","author":"Garnache-Ottou","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.12.010_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: an update","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.clml.2023.12.010_bib0024","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2009.07679.x","article-title":"Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia","volume":"145","author":"Garnache-Ottou","year":"2009","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2023.12.010_bib0025","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Mu\u00f1oz","year":"2001","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.clml.2023.12.010_bib0026","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2023.12.010_bib0027","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.12.010_bib0028","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","article-title":"Monoclonal antibody targeting of IL-3 receptor \u03b1 with CSL362 effectively depletes CML progenitor and stem cells","volume":"123","author":"Nievergall","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.12.010_bib0029","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/leu.2015.16","article-title":"Aberrant expression of CD123 (interleukin-3 receptor-\u03b1) on neoplastic mast cells","volume":"29","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.12.010_bib0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2015.348","article-title":"CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2023.12.010_bib0031","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3324\/haematol.2020.253740","article-title":"Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape","volume":"106","author":"Zalma\u00ef","year":"2021","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.clml.2023.12.010_bib0032","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood-2011-03-337501","article-title":"Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion","volume":"118","author":"Lucioni","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.12.010_bib0033","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjd.12412","article-title":"Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients","volume":"169","author":"Julia","year":"2013","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.clml.2023.12.010_bib0034","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cyto.b.21932","article-title":"Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review","volume":"100","author":"Espasa","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2023.12.010_bib0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-018-0117-6","article-title":"Early detection of transformation to BPDCN in a patient with MDS","volume":"7","author":"Chamoun","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"24","key":"10.1016\/j.clml.2023.12.010_bib0036","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1182\/bloodadvances.2021005802","article-title":"Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey","volume":"5","author":"Valentini","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.clml.2023.12.010_bib0037","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.2021011817","article-title":"Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.12.010_bib0038","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Mart\u00edn-Mart\u00edn","year":"2016","journal-title":"Oncotarget"},{"issue":"suppl 3","key":"10.1016\/j.clml.2023.12.010_bib0039","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.HS9.0000845008.01963.5f","article-title":"Tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with\/without central nervous system involvement and intrathecal chemotherapy as primary treatment or prophylaxis: an Italian experience","volume":"6","author":"Rivoli","year":"2022","journal-title":"Hemasphere"},{"issue":"20","key":"10.1016\/j.clml.2023.12.010_bib0040","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1212\/01.wnl.0000261909.28915.83","article-title":"CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies","volume":"68","author":"Bromberg","year":"2007","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.clml.2023.12.010_bib0041","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2013-11-537993","article-title":"Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome","volume":"123","author":"Mu\u00f1iz","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.12.010_bib0042","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cyto.a.22072","article-title":"Intractyoplasmic detection of TCL1\u2014but not ILT7\u2014by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis","volume":"81","author":"Angelot-Delettre","year":"2012","journal-title":"Cytometry A"},{"issue":"3","key":"10.1016\/j.clml.2023.12.010_bib0043","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cll.2017.05.005","article-title":"Myeloid neoplasms","volume":"37","author":"Subtil","year":"2017","journal-title":"Clin Lab Med"},{"issue":"9","key":"10.1016\/j.clml.2023.12.010_bib0044","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1097\/PAS.0b013e31825dd4de","article-title":"Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases","volume":"36","author":"Vitte","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.clml.2023.12.010_bib0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2023.12.010_bib0046","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2133.2009.09373.x","article-title":"Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?","volume":"162","author":"Dalle","year":"2010","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.clml.2023.12.010_bib0047","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/cncr.21268","article-title":"Blastic natural killer cell lymphoma\/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement","volume":"104","author":"Suzuki","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.12.010_bib0048","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00277-012-1614-z","article-title":"Blastic plasmacytoid dendritic cell neoplasm: a single-center experience","volume":"92","author":"An","year":"2013","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.clml.2023.12.010_bib0049","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.12.010_bib0050","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2018-99-119945","article-title":"Developmental ontogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN) revealed by recurrent high burden clonal hematopoiesis, including in \u201cskin-only\u201d disease","volume":"132","author":"Griffin","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.12.010_bib0051","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.clml.2023.12.010_bib0052","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/S2352-3026(19)30050-X","article-title":"The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukemia: a retrospective analysis of the St Jude Lifetime Cohort Study","volume":"6","author":"Mulrooney","year":"2019","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1016\/j.clml.2023.12.010_bib0053","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2023.12.010_bib0054","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2023.12.010_bib0055","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"121","author":"Roos-Weil","year":"2013","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2023.12.010_bib0056","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/bloodadvances.2020001875","article-title":"Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant","volume":"4","author":"Yun","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2023.12.010_bib0057","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.hoc.2020.01.009","article-title":"Hematopoietic cell transplant for blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Kharfan-Dabaja","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.clml.2023.12.010_bib0058","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41409-021-01478-5","article-title":"Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"57","author":"Bashir","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2023.12.010_bib0059","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2010.12.706","article-title":"Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity","volume":"17","author":"Dietrich","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.clml.2023.12.010_bib0060","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","article-title":"Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"125","author":"Aoki","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.12.010_bib0061","unstructured":"ELZONRIS\u00ae (tagraxofusp-erzs) [prescribing information]. New York, NY: Stemline Therapeutics, Inc.; 2018."},{"key":"10.1016\/j.clml.2023.12.010_bib0062","unstructured":"ELZONRIS [summary of product characteristics]. Amsterdam, the Netherlands: Stemline Therapeutics B.V.; 2021."},{"issue":"8","key":"10.1016\/j.clml.2023.12.010_bib0063","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.clml.2023.12.010_bib0064","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.00034","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.12.010_bib0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-018-0604-6","article-title":"First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases","volume":"11","author":"Sun","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.12.010_bib0066","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1182\/blood-2021-147486","article-title":"Safety and efficacy of combining tagraxofusp (SL-401) with azacitidine or azacitidine and venetoclax in a phase 1b study for CD123 positive AML, MDS, or BPDCN","volume":"138","author":"Lane","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.12.010_bib0067","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1016\/j.clml.2021.02.008","article-title":"Combination of tagraxofusp and azacitidine is an effective option for relapsed blastic plasmacytoid dendritic cell neoplasm after allogeneic hematopoietic stem-cell transplantation","volume":"21","author":"Wang","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2023.12.010_bib0068","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/1078155220951850","article-title":"Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: a case report and literature review","volume":"27","author":"Samhouri","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"51","key":"10.1016\/j.clml.2023.12.010_bib0069","doi-asserted-by":"crossref","first-page":"e9452","DOI":"10.1097\/MD.0000000000009452","article-title":"Novel treatment of blastic plasmacytoid dendritic cell neoplasm: a case report","volume":"96","author":"Grushchak","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.12.010_bib0070","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2021-150393","article-title":"Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in pediatric patients with tagraxofusp, a CD123-targeted therapy","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T02:14:14Z","timestamp":1712542454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2152265023021985"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}